JP2020537525A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020537525A5 JP2020537525A5 JP2020521290A JP2020521290A JP2020537525A5 JP 2020537525 A5 JP2020537525 A5 JP 2020537525A5 JP 2020521290 A JP2020521290 A JP 2020521290A JP 2020521290 A JP2020521290 A JP 2020521290A JP 2020537525 A5 JP2020537525 A5 JP 2020537525A5
- Authority
- JP
- Japan
- Prior art keywords
- replicative
- vector according
- saladenovirus
- vector
- expression cassette
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000013598 vector Substances 0.000 claims description 49
- 230000003362 replicative effect Effects 0.000 claims description 25
- 241000282693 Cercopithecidae Species 0.000 claims description 22
- 239000000427 antigen Substances 0.000 claims description 21
- 108091007433 antigens Proteins 0.000 claims description 21
- 102000036639 antigens Human genes 0.000 claims description 21
- 241000701161 unidentified adenovirus Species 0.000 claims description 20
- 241000282577 Pan troglodytes Species 0.000 claims description 8
- 108700019146 Transgenes Proteins 0.000 claims description 6
- 201000010099 disease Diseases 0.000 claims description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 4
- 230000001124 posttranscriptional effect Effects 0.000 claims description 4
- 230000001105 regulatory effect Effects 0.000 claims description 4
- 108700026758 Adenovirus hexon capsid Proteins 0.000 claims description 3
- 241000701022 Cytomegalovirus Species 0.000 claims description 3
- 238000010255 intramuscular injection Methods 0.000 claims description 3
- 239000007927 intramuscular injection Substances 0.000 claims description 3
- 239000002773 nucleotide Substances 0.000 claims description 3
- 125000003729 nucleotide group Chemical group 0.000 claims description 3
- 230000002265 prevention Effects 0.000 claims description 3
- 230000010076 replication Effects 0.000 claims description 3
- 241001217856 Chimpanzee adenovirus Species 0.000 description 4
- 241000700605 Viruses Species 0.000 description 4
- 238000000034 method Methods 0.000 description 3
- 208000010772 Dog disease Diseases 0.000 description 2
- 241000711549 Hepacivirus C Species 0.000 description 2
- 241000700721 Hepatitis B virus Species 0.000 description 2
- 241000725303 Human immunodeficiency virus Species 0.000 description 2
- 201000004792 malaria Diseases 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 230000000241 respiratory effect Effects 0.000 description 2
- 201000008827 tuberculosis Diseases 0.000 description 2
- 108010056962 Adenovirus E4 Proteins Proteins 0.000 description 1
- 206010011732 Cyst Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 241000283923 Marmota monax Species 0.000 description 1
- 208000031513 cyst Diseases 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762572927P | 2017-10-16 | 2017-10-16 | |
| US62/572,927 | 2017-10-16 | ||
| PCT/EP2018/078206 WO2019076877A1 (en) | 2017-10-16 | 2018-10-16 | ADENOVIRAL VECTORS FOR REPLICATION |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020537525A JP2020537525A (ja) | 2020-12-24 |
| JP2020537525A5 true JP2020537525A5 (cg-RX-API-DMAC7.html) | 2021-11-18 |
| JPWO2019076877A5 JPWO2019076877A5 (cg-RX-API-DMAC7.html) | 2022-06-20 |
Family
ID=63965644
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020521290A Pending JP2020537525A (ja) | 2017-10-16 | 2018-10-16 | 複製能力のあるアデノウイルスベクター |
Country Status (14)
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112021025025A2 (pt) | 2019-06-11 | 2022-02-22 | Glaxosmithkline Biologicals Sa | Formulações de vacinas de mucosa |
| JP7454645B2 (ja) | 2019-07-16 | 2024-03-22 | ギリアード サイエンシーズ， インコーポレイテッド | Ｈｉｖワクチン並びにその作製方法及び使用方法 |
| IL315295A (en) | 2019-09-30 | 2024-10-01 | Gilead Sciences Inc | Hbv vaccines and methods treating hbv |
| WO2021229473A1 (en) | 2020-05-14 | 2021-11-18 | Glaxosmithkline Biologicals Sa | Viral biosensors |
| CN114591922A (zh) * | 2022-03-30 | 2022-06-07 | 长睿生物技术(成都)有限公司 | 一种表达狂犬病毒g蛋白的重组黑猩猩源腺病毒及其制备方法 |
| CA3259040A1 (en) | 2022-07-12 | 2024-01-18 | Gilead Sciences, Inc. | HIV Immunogenic Polypeptides and Vaccines and Their Uses |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1998010087A1 (en) * | 1996-09-06 | 1998-03-12 | Trustees Of The University Of Pennsylvania | Chimpanzee adenovirus vectors |
| EP3385387B1 (en) | 2009-02-02 | 2021-08-25 | GlaxoSmithKline Biologicals SA | Simian adenovirus nucleic acid- and amino acid-sequences, vectors containing same, and uses thereof |
| WO2011014794A1 (en) * | 2009-07-31 | 2011-02-03 | Paxvax, Inc. | Adenoviral-based vectors |
| CN103492574B (zh) | 2011-02-22 | 2015-12-09 | 加州理工学院 | 使用腺相关病毒（aav）载体递送蛋白 |
| GB201322851D0 (en) * | 2013-12-23 | 2014-02-12 | Psioxus Therapeutics Ltd | Method |
| BE1024420B1 (fr) | 2015-06-12 | 2018-02-19 | Glaxosmithkline Biologicals Sa | Polynucleotides et polypeptides d'adenovirus |
| GB201513010D0 (en) * | 2015-07-23 | 2015-09-09 | Glaxosmithkline Biolog Sa | Novel formulation |
| GB201513176D0 (en) * | 2015-07-27 | 2015-09-09 | Glaxosmithkline Biolog Sa | Novel methods for inducing an immune response |
| GB201620968D0 (en) * | 2016-12-09 | 2017-01-25 | Glaxosmithkline Biologicals Sa | Adenovirus polynucleotides and polypeptides |
-
2018
- 2018-10-16 CN CN201880080955.9A patent/CN111655847A/zh active Pending
- 2018-10-16 MX MX2020003385A patent/MX2020003385A/es unknown
- 2018-10-16 JP JP2020521290A patent/JP2020537525A/ja active Pending
- 2018-10-16 BR BR112020007238-9A patent/BR112020007238A2/pt not_active IP Right Cessation
- 2018-10-16 WO PCT/EP2018/078206 patent/WO2019076877A1/en not_active Ceased
- 2018-10-16 US US16/756,376 patent/US11268108B2/en active Active
- 2018-10-16 AR ARP180103004A patent/AR113450A1/es not_active Application Discontinuation
- 2018-10-16 KR KR1020207013668A patent/KR20200066349A/ko not_active Withdrawn
- 2018-10-16 SG SG11202003058UA patent/SG11202003058UA/en unknown
- 2018-10-16 EP EP18792880.9A patent/EP3697899A1/en active Pending
- 2018-10-16 EA EA202090700A patent/EA202090700A1/ru unknown
- 2018-10-16 AU AU2018351308A patent/AU2018351308B2/en not_active Expired - Fee Related
- 2018-10-16 CA CA3079043A patent/CA3079043A1/en active Pending
-
2020
- 2020-04-01 IL IL273753A patent/IL273753A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020537525A5 (cg-RX-API-DMAC7.html) | ||
| Travieso et al. | The use of viral vectors in vaccine development | |
| Humphreys et al. | Novel viral vectors in infectious diseases | |
| Kosinska et al. | Therapeutic vaccination for chronic hepatitis B | |
| Mühlebach | Vaccine platform recombinant measles virus | |
| JP2019526580A5 (cg-RX-API-DMAC7.html) | ||
| Kuate et al. | Exosomal vaccines containing the S protein of the SARS coronavirus induce high levels of neutralizing antibodies | |
| JP2017515508A5 (cg-RX-API-DMAC7.html) | ||
| Reynolds et al. | Virus-like vesicle-based therapeutic vaccine vectors for chronic hepatitis B virus infection | |
| Hasanpourghadi et al. | COVID-19 vaccines based on adenovirus vectors | |
| JP2020516264A5 (cg-RX-API-DMAC7.html) | ||
| JP2009539965A5 (cg-RX-API-DMAC7.html) | ||
| JP2016539946A5 (cg-RX-API-DMAC7.html) | ||
| JP2019505560A5 (cg-RX-API-DMAC7.html) | ||
| JP5675789B2 (ja) | 免疫接種のための発現ベクターとしての水疱性口内炎ウイルスの異なる複数の抗原型 | |
| Hanke | New vector and vaccine platforms: mRNA, DNA, viral vectors | |
| Bassi et al. | Vaccination with replication deficient adenovectors encoding YF-17D antigens induces long-lasting protection from severe yellow fever virus infection in mice | |
| JP2021500880A5 (cg-RX-API-DMAC7.html) | ||
| JP2020537526A5 (cg-RX-API-DMAC7.html) | ||
| Flaxman et al. | Potent immunogenicity and protective efficacy of a multi-pathogen vaccination targeting Ebola, Sudan, Marburg and Lassa viruse | |
| RU2639504C2 (ru) | Химерные антигены для вакцины против вируса гепатита с | |
| JP4989224B2 (ja) | Ｄｎａワクチン組成物およびその使用方法 | |
| JPWO2019076877A5 (cg-RX-API-DMAC7.html) | ||
| ES2608627T5 (es) | Uso de un poxvirus modificado para inducción rápida de inmunidad frente a un poxvirus u otros agentes infecciosos | |
| DK177298B1 (en) | Nucleic Acid and Amino Acid Sequences of Infectious Salmon Anaemia Virus and their Use as Vaccines |